Abivax S.A. is a French biotech company developing new medicines.
Abivax S.A. (ABVX) is expected to report earnings on Monday, December 21, 2026, after the close. Consensus EPS estimate is $-1.27.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-09-21 | Jun 2026 qtr | $-1.03 | $-1.71 | — | $1.37M |
| 2025-09-08 | Jun 2025 qtr | $-0.90 | $-1.59 | — | $0 |
| 2025-03-24 | Dec 2024 qtr | $-0.76 | $-1.50 | — | $0 |
| 2024-06-30 | Jun 2024 qtr | — | $-0.65 | — | $0 |
| 2023-12-31 | Dec 2023 qtr | — | $-1.98 | — | $2.33M |
| 2023-06-30 | Jun 2023 qtr | — | $-1.45 | — | $2.25M |
| 2022-12-31 | Dec 2022 qtr | $-1.93 | $-1.81 | +6.2% | $2.25M |
| 2022-06-30 | Jun 2022 qtr | — | $-1.76 | — | $2.23M |
ABVX has beaten consensus EPS in 1 of its last 1 scored quarters.
See ABVX on the live calendar →